Guideline‑Directed Management of Cardiogenic Shock in Acute Decompensated Heart Failure

Immediate Assessment & Transfer

Patients presenting with hypotension (SBP ≈ 93 mmHg), bradycardia (HR ≈ 49 bpm), markedly elevated BNP, and worsening renal function should be admitted immediately to an ICU/CCU for cardiogenic‑shock treatment (European Society of Cardiology). 1
Transfer to a tertiary centre that provides 24/7 cardiac‑catheterisation capability and mechanical‑circulatory‑support (MCS) resources is recommended (European Society of Cardiology). 1

Continuous 12‑lead ECG and invasive arterial blood‑pressure monitoring are mandatory in cardiogenic shock (European Society of Cardiology). 1
Obtain an urgent ECG and bedside echocardiography to evaluate cardiac function, exclude acute coronary syndrome, and detect mechanical complications (European Society of Cardiology). 1
Pulmonary‑artery catheterisation should be considered when planning MCS to obtain detailed haemodynamic data (European Society of Cardiology). 1
Daily weight, strict fluid‑balance charting, and serial assessment of renal function and electrolytes are required (European Society of Cardiology; European Heart Failure Association). [2][3]

Systolic blood pressure < 115 mmHg and heart rate < 60 bpm identify a high‑risk subgroup for in‑hospital mortality in acute decompensated heart failure (European Society of Cardiology). [2][3]
The combination of low SBP and elevated BUN (≥ 22.5 mg/dL) predicts an in‑hospital mortality risk of ≈ 22 % (European Society of Cardiology). 3

Symptomatic bradycardia must be evaluated promptly because it contributes substantially to hypotension and low cardiac output (European Society of Cardiology). [4][5]6
Immediately discontinue any rate‑lowering agents (β‑blockers, digoxin, amiodarone, calcium‑channel blockers) (Canadian Cardiovascular Society). [4][5][6][7]
Perform a 12‑lead ECG to rule out high‑grade AV block or sick‑sinus syndrome (European Society of Cardiology). 1
If bradycardia persists after medication withdrawal, temporary transvenous pacing should be instituted (European Society of Cardiology). [4][5]6
Digoxin is contraindicated in the presence of bradycardia, second‑ or third‑degree AV block, or sick‑sinus syndrome (European Society of Cardiology). [4][5]6

Norepinephrine is the preferred first‑line vasopressor to maintain mean arterial pressure and organ perfusion; it is recommended over dopamine (European Society of Cardiology). 1

Dobutamine (initial dose 2–5 µg·kg⁻¹·min⁻¹) is the most commonly used adrenergic inotrope for cardiogenic shock (European Society of Cardiology). 1
In patients already receiving chronic β‑blockade, add milrinone (0.375–0.75 µg·kg⁻¹·min⁻¹) without a loading dose because hypotension precludes loading (European Society of Cardiology). 1
Levosimendan may be employed as an alternative inotrope in combination with a vasopressor when dobutamine is unsuitable (European Society of Cardiology). 1

Loop diuretics should be used cautiously; give furosemide 20–40 mg IV bolus only when clear signs of volume overload are present (European Heart Failure Association). 8
Patients with SBP < 90 mmHg are unlikely to achieve adequate decongestion with diuretics alone (European Heart Failure Association). 8
Urine output must be monitored closely, preferably with a bladder catheter (European Heart Failure Association). 8
Aggressive diuresis that could further lower blood pressure or impair renal function should be avoided (European Heart Failure Association). 8

Daily monitoring of renal function is essential; a worsening trend despite optimal therapy signals the need for escalation of support (European Society of Cardiology; European Heart Failure Association). [2][3]

Early consideration of short‑term MCS is advised when adequate haemodynamic response to combined inotropes and vasopressor therapy is not achieved (European Society of Cardiology). 1
Percutaneous ventricular‑assist devices or extracorporeal membrane oxygenation (ECMO) are the preferred MCS modalities (European Society of Cardiology). 1
Routine use of intra‑aortic balloon pump (IABP) is not recommended because it does not improve outcomes in cardiogenic shock (European Society of Cardiology). 1
Decisions regarding MCS should involve a multidisciplinary shock team comprising heart‑failure specialists, interventional cardiologists, and cardiac surgeons (American College of Cardiology). 10

If acute coronary syndrome cannot be excluded, immediate coronary angiography (within 2 hours) with intent to revascularise is mandated (European Society of Cardiology). 1

β‑Blockers should be temporarily reduced or held during acute decompensation with bradycardia and hypotension, but not discontinued unless the patient is in overt cardiogenic shock (Canadian Cardiovascular Society; European Society of Cardiology). [7][11]
ACE‑inhibitors/ARBs should be temporarily withheld in the setting of hypotension (European Society of Cardiology). 11
Mineralocorticoid‑receptor antagonists should be paused when renal dysfunction is present (European Society of Cardiology). 11
After haemodynamic stabilisation, guideline‑directed medical therapy (GDMT) should be re‑initiated at low doses and uptitrated cautiously (European Society of Cardiology). 11

Aggressive diuresis in a hypotensive patient worsens cardiac output and renal perfusion (European Heart Failure Association). 8
Continuing rate‑lowering medications in symptomatic bradycardia and cardiogenic shock must be avoided (European Society of Cardiology). [4][5]6
Delaying escalation to MCS when pharmacologic therapy is insufficient increases mortality (European Society of Cardiology; American College of Cardiology). [1][10]
Routine use of IABP should be avoided because it does not improve survival (European Society of Cardiology). 1
Permanent discontinuation of GDMT is discouraged; a plan for re‑introduction after stabilisation is required (European Society of Cardiology). 11

Patients should remain hospitalised until they are haemodynamically stable, euvolemic, and have stable renal function for at least 24 hours before discharge (European Heart Failure Association). 3